Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2026-06-01 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement of resolutions and detailed voting results from the company’s 2026 first extraordinary shareholders’ meeting, including attendance figures, vote counts, percentages, and legal opinions. It clearly reports the outcome of shareholder votes, which aligns with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-06-01 Chinese
关于变更独立董事的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by Zhejiang Tailin Biotech regarding the resignation of an independent director and the election of a new independent director to the board. It details changes in board composition and governance structure rather than presenting financial results or providing meeting materials. This fits the definition of a Board/Management Information filing.
2026-06-01 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2026年第一次临时股东会法律意见书
Regulatory Filings Classification · 82% confidence The document is a standalone legal opinion letter (法律意见书) issued by a law firm concerning the convening, procedures, attendance, voting, and validity of an Extraordinary General Meeting of Zhejiang Tailin Biotech. It does not present financial data (so not an IR/10-K), nor is it a proxy solicitation (no voting request materials) or a pure voting results announcement (it includes legal compliance opinion). It is a compliance/legal document filed with the exchange that does not fit any more specific category, so it defaults to Regulatory Filings (RNS).
2026-06-01 Chinese
独立董事候选人关于参加最近一次独立董事培训的书面承诺
Regulatory Filings Classification · 57% confidence The document is a written commitment by an independent director candidate to attend required training and obtain certification, as mandated by the exchange. It is not announcing financial results, an AGM presentation, an actual director change, or any transaction. It is a compliance-related filing falling under miscellaneous regulatory announcements. Therefore it is classified as a generic Regulatory Filing (RNS).
2026-05-15 Chinese
关于独立董事任期届满辞职暨补选独立董事的公告
Board/Management Information Classification · 90% confidence The document is an official announcement titled “关于独立董事任期届满辞职暨补选独立董事的公告,” describing the resignation of an independent director upon term expiration and the board’s plan to nominate and elect a replacement independent director. It discusses changes to the board composition and director appointments. This matches the Board/Management Information category (MANG).
2026-05-15 Chinese
关于调整2026年员工持股计划购买价格的公告
Share Issue/Capital Change Classification · 75% confidence The document is an official announcement by the company’s board regarding an adjustment to the 2026 employee share ownership plan’s purchase price. It relates to changes in the terms of a planned share issue (employee stock plan) rather than financial results or a general regulatory filing. This falls under Share Issue/Capital Change activities (new share issues or capital structure changes).
2026-05-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.